Shares of Editas Medicine Inc (NASDAQ:EDIT) were down 0% during trading on Monday . The stock traded as low as $27.00 and last traded at $30.02. Approximately 6,027,616 shares were traded during trading, an increase of 343% from the average daily volume of 1,360,000 shares. The stock had previously closed at $30.02.

Several analysts have commented on EDIT shares. ValuEngine upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Morgan Stanley reiterated an “equal weight” rating and set a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a research report on Friday, October 6th. Zacks Investment Research cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cowen reiterated a “buy” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Finally, Cann reiterated a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $26.73.

The company has a market capitalization of $1,370.00 and a P/E ratio of -9.62. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to analyst estimates of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. Editas Medicine’s revenue for the quarter was up 553.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.59) earnings per share. research analysts anticipate that Editas Medicine Inc will post -2.92 EPS for the current fiscal year.

In related news, insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $23.64, for a total value of $196,992.12. Following the completion of the transaction, the insider now directly owns 1,393,322 shares of the company’s stock, valued at approximately $32,938,132.08. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew A. F. Hack sold 5,000 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $24.81, for a total transaction of $124,050.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $124,050. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,310 shares of company stock valued at $1,689,449. Company insiders own 19.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of EDIT. IHT Wealth Management LLC acquired a new position in shares of Editas Medicine during the 2nd quarter worth about $107,000. Great West Life Assurance Co. Can boosted its stake in shares of Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after buying an additional 4,159 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Editas Medicine by 308.4% during the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after buying an additional 6,535 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Editas Medicine by 4.1% during the 2nd quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock worth $157,000 after buying an additional 372 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new position in shares of Editas Medicine during the 2nd quarter worth about $258,000. Institutional investors own 65.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/editas-medicine-edit-trading-down-0/1801419.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with Analyst Ratings Network's FREE daily email newsletter.